# Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

> **NCT01430416** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** AEB071

## Key facts

- **NCT ID:** NCT01430416
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-20
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430416, "Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01430416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*